Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 17/20 | 0.51 |
| ▸ | PI4KA | P42356 | 1/20 | 0.47 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.47 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.47 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.45 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.45 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5163111 | 0.94 | TLR7 (0.53) | TLR7PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL5161917 | 0.92 | TLR7 (0.51) | TLR7ADORA2AADORA2B | |
| SCHEMBL5159098 | 0.87 | TLR7 (0.52) | TLR7 | |
| SCHEMBL5162427 | 0.78 | ABCB1 (0.48) | TLR7PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL5158930 | 0.78 | ADORA2A (0.50) | TLR7ADORA2AADORA2BADORA3ADORA1 | |
| SCHEMBL5161117 | 0.77 | ADORA2A (0.59) | PI4KAPI4K2BPI4K2API4KBADORA2A | |
| SCHEMBL5160552 | 0.76 | TLR7 (0.54) | TLR7ADORA2AADORA2BADORA3ADORA1 | |
| SCHEMBL5177679 | 0.76 | PI4KA (0.46) | TLR7PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL5163812 | 0.76 | ADORA1 (0.60) | TLR7PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL3441050 | 0.75 | PI4KA (0.49) | TLR7PI4KAPI4K2BPI4K2API4KB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7189730-B2 | A2A adenosine receptor antagonists | CV THERAPEUTICS, INC. (US) | 2007-03-13 | — | — | US | disclosed |
| EP-1456209-B1 | A2A ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS INC (US) | 2007-02-28 | — | — | EP | disclosed |
| US-20030149060-A1 | A2A adenosine receptor antagonists | CV THERAPEUTICS, INC. | 2003-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149060-A1 | A2A adenosine receptor antagonists | ADORA2A, ADORA2B, ADORA3 | TLR7 1301/4885PI4KA 1091/4885PI4K2B 773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.